Pelthos Therapeutics Inc (PTHS) — Titan Protect Analysis

PTHS

Pelthos Therapeutics Inc

Healthcare · ·

$25.55

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$92M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-12.42

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

-186.2%

How much profit the company keeps from each dollar of revenue

ROE

-333.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$55.00

+115% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Pelthos Therapeutics Inc

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indi

https://pelthos.com

Country: United States Employees: 92 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.844

Good returns relative to risk taken

Kelly Fraction

0.0540

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.472

Drawdown risk outweighs the returns — higher risk profile

Annual Return

31.5%

Historical annualised return based on price data

Max Drawdown

-66.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

169

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

3.33

Significantly more volatile than the market

52W High

$54.29

53% below the year high

52W Low

$10.43

145% above the year low

Avg Volume

15,144

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-22.92

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

150.79

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

75.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-120.0%

Profit from core operations before interest and tax

Free Cash Flow

$-34,339,868

Negative — the business is spending more than it generates

Revenue (TTM)

$28M

Total revenue over the last 12 months

Net Income

$-51,589,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$75.00

Target Median

$55.00

Target Low

$48.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go